Search

Results

• About Kurma

  1. Our Vision We have high standards We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe ...

• News
• Contact

  FRANCE Kurma Partners 24, rue Royale / 5e étage 75008 Paris France Tel. : +33 (0)1 84 86 08 61 contact@kurmapartners.com GERMANY Kurma Partners Maximilianstraße 29 80539 Munchen Germany Tel. : +49 (0) 89-236 ...

• Legale notice

  WEBSITE EDITOR COMPANY Kurma Partners - Public limited company with a board of directors and supervisory board, with a capital of 438 561.58 euros, whose head office is located at 24 rue royale - 75008 Paris, registered in the Paris trade and companies register under the number 510 043 136 ...

• DATA PROTECTION NOTICE

       DATA PROTECTION NOTICE The protection of your personal data is important to Kurma Partners, which has adopted strong principles in that respect. This Data Protection Notice provides you with detailed information relating to the protection of your personal data by Kurma Part ...

• portfolio

  Discover the companies that have grown with us

• Work with us

  Lorem ipsum dolor sit amet, consectetur adipisicing elit. Aliquam at beatae deserunt dolorum id ipsa ipsum non odit, officia, repellat sapiente soluta unde vitae. Autem delectus doloribus ex optio vitae. Animi consectetur debitis dicta eius enim hic illo impedit iusto labore minus omnis, poss ...

• Regulatory information

  VOTING POLICY The exercise of voting rights in AGMs is an essential part of our fiduciary responsibility and our role as a responsible investor. As such, KURMA PARTNERS SA has implemented its defining the procedures for exercising voting rights attached to the instruments held by the managed ...

• Team

          

• Our Funds
• Videos
• Terms and conditions

            By using this site and the information it contains, users acknowledge that they understand and accept the following terms of use. The purpose of this website is to provide general information on Kurma Partners’s activities. Kurma Partners endeavors ...

• Dr Bastian Dehmel Appointed CMO of OxThera
• Kurma Partners annonce le closing final de son fonds Kurma Biofund III à 160M€

  • Validation du modèle de Kurma Partners avec le closing de son troisième fonds dédié aux Sciences de la Vie, pour un montant significativement supérieur aux deux premiers fonds • Kurma Partners passe d’environ 250M€ sous gestion &agrav ...

• Dynacure secures €47 million financing to advance lead program into clinical development

  Financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs for other orphan disorders [...]

• Chief Medical Officer appointed for clinical trials of world's first therapy targeting both PMDD and menstrual migraine

  A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for PMDD [...]

• Dynacure : une success-story issue de la recherche publique alsacienne, qui bat des records nationaux.

  Créée à la mi-2016, la startup alsacienne Dynacure, spécialisée dans le traitement des maladies neuromusculaires rares, vient d’annoncer une levée de fonds historique d’un montant de 47 M€, qui l’élève au rang des records ...

• Share issue in Asarina Pharma AB (publ) oversubscribed before listing on First North

  On 24 August 2018, the Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”), resolved, with the authorization from the Extraordinary General Meeting on 28 June, 2018, on a share issue of up to 6,800,000 shares (the “Offer”) and to apply for admission to trad ...

• Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA

  Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASN120290 for the treatment of progressive supranuclear palsy (PSP ...

• ImCheck Therapeutics Appoints Prof. René Hoet, PhD, as Chief Scientific Officer

  ImCheck Therapeutics, an emerging biopharmaceutical company developing novel immune modulators against cancer and auto-immune diseases, announced today the appointment of René Hoet, PhD, as its Chief Scientific Officer. René Hoet is a molecular immunologist with over 20 years’ experience in an ...

• HORAMA completes its 22.5 million euros “Series B” financing round

  Horama (www.horama.fr), a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare genetic diseases in ophthalmology, announces today that the Belgian fund V-Bio Ventures joins the company’s “Series B” financing round. Willem Broekaert, Mana ...

• Asarina Pharma IPO oversubscribed 175%: CEO welcomes new shareholders

  With its IPO listing oversubscribed by 175%, Asarina Pharma is firmly in the investor and scientific spotlight. Here, CEO Peter Nordkild shares upcoming research and business highlights with the company’s new shareholders. [...]

• HORAMA completes its 22.5 million euros “Series B” financing round

  Horama (www.horama.fr), a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare genetic diseases in ophthalmology, announces today that the Belgian fund V-Bio Ventures joins the company’s “Series B” financing round. Willem Broekaert, Mana ...

• Minoryx Therapeutics raises €21.3M in Series B funding round

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new ...

• Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)

  Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C ( ...

• Stilla Technologies completes €16 Million ($18 Million) Series A

  Stilla Technologies, the European provider of pioneering digital PCR solutions for high precision genetic analysis, announced today the successful completion of a Series A financing round of 16 million euros ($18 Million) led by Illumina Ventures, with participation from from Kurma Partners, LBO Fra ...

• Reinventing the Health sector start-up financing model

  Kurma Partners, a French venture capital company specialising in the Life Sciences sector, today presents its investment convictions to encourage innovation and accelerate the creation of new Health-sector companies. [...]

• AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury

  Recruitment of 301 patients in STOP-AKI adaptive Phase II trial marks largest ever therapeutic study in AKI. [...]

• Kurma Partners announces investments in Asceneuron SA and Minoryx Therapeutics SL

  Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces two new investments of Kurma Biofund II [...]

• Kurma Partners expands its investment team with the appointment of Alain Horvais and Philippe Peltier as Partners and announces the promotion of Vanessa Malier as Managing Partner

  Paris, June 23th 2015. Alain Horvais and Philippe Peltier join Kurma Partners to serve as Partners in charge of the management of Kurma Diagnostics [...]

• Kurma Partners announces the launch of its third fund Kurma Diagnostics (KDx)

  The European Investment Fund (EIF), Fonds National d’Amorçage (FNA) managed by Bpifrance as part of the French government’s Investments for [...]

• KURMA ANNOUNCES THE FIRST INVESTMENT OF THEIR NEWLY LAUNCHED DIAGNOSTICS FUNDS IN THE START UP COMPANY BIOSERENITY

  The French start-up specialized in wearable medical device solutions raises 3 million Euros in a Seed round to grow in the medical diagnostic field. [...]

• Kurma Partners has moved

  Our new head office is located at 24 Rue Royale - 75008 Paris, France. Our office number is now: +33 (0)1 84 860 861 [...]

• Kurma Biofund I portfolio company AM Pharma enters into a major transaction with Pfizer

  Kurma Partners announces that Pfizer acquires minority interest in AM Pharma, a Kurma Biofund I portfolio company, and secures an option to [...]

• Kurma Biofund, a recently launched life science fund, announces a new relationship with Imperial Innovations plc

  Kurma Biofund (Kurma) is a new venture capital fund based in Paris and dedicated to innovations in Life Sciences and Healthcare [...]

• KURMA Partners invests in Orphazyme ApS

  KURMA Partners invests in Orphazyme ApS, a leading European biopharmaceutical company developing Heat Shock Protein based treatment for lysosomal storage diseases and [...]

• MEIOGENIX SAS, A FRENCH GENOMIC START-UP COMPANY, RAISES 1,2M € FROM INVESTORS

  Meiogenix SAS, a French start-up biotech company developing of a new genomic technology, closed its first round of financing of 1,2M € [...]

• KURMA Partners invests in Xeltis, a leading regenerative medicine company with first product targeting orphan and severe cardiac malformations

  Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces its investment in Xeltis, a private Swiss/Dutch [...]

• Imperial Innovations and Kurma BioFund I conclude £0.93m seed investment in Indigix Ltd

  Imperial Innovations Group plc (AIM: IVO, or „Innovations‟), a leading technology commercialisation and investment company [...]

• Dynacure appoints its Management Team and members of the Board of Directors

  Dynacure’s leadership team includes Stephane van Rooijen (CEO), Frédéric Legros (COO) and Leen Thielemans (Head of Development). The team will focus on the company’s preclinical and clinical development programs in CNM and the expansion of its pipeline in rare disease treatments. [...]

• Idinvest Partners cements ties with Kurma Life Sciences Partners

  In keeping with their history of close collaboration, the companies announced today that Idinvest Partners was acquiring a stake in KLS Partners. [...]

• Kurma Life Sciences Partners announces that Vanessa Malier joins as Partner

  Vanessa joins today Kurma Life Sciences Partners as Partner, bringing 15 years of experience in Biotech and pharmaceutical industry [...]

• Kurma Life Sciences Partners and the SATT Conectus Alsace unite their strengths to accelerate the new business start-up exits of the public researc

  Kurma Life Sciences Partners, company of venture capital spectialist of the Health and the Biotechnologies, and the SATT Conectus Alsace company of [...]

• Idinvest Partners and Kurma Life Sciences Partners announce the first step of the acquisition of Novagali Pharma S.A. by Santen Pharmaceutical Co., Ltd

  On Tuesday September 27th, Santen Pharmaceutical Co., Ltd. (Osaka, Japon), a leading Japanese pharmaceutical company, and [...]

• Kurma Life Sciences Partners and Idinvest Partners announce the EUR 29,2 Million Series D Financing of AM Pharma

  Kurma Life Science Partners and Idinvest Partners today announced that they have participated in a EUR 29,2 million Series D financing round of [...]

• Kurma Life Sciences Partners and Cydan Enter Collaboration

  Kurma Life Sciences Partners today announced collaboration with Cydan Development, Inc., an orphan drug accelerator that identifies strategic [...]

• Kurma Life Sciences Partners and Idinvest Partners announce the success of IPO of Prosensa Holding B.V

  On Friday June 28th, Prosensa Holding B.V. (Prosensa) initiated its first trading day on the Nasdaq New York, US. Prosensa [...]

• Kurma Life Sciences Partners announces the launch of Kurma Biofund II: The Orphan Initiative

  KLS Partners, GlaxoSmithKline (GSK), bpifrance (CDC Entreprises), Idinvest Partners and New Enterprise Associates (NEA) are participating in the first closing (€44M). [...]

• Karolinska Development and Kurma Biofund to enter strategic partnership

  Karolinska Development AB and Kurma Biofund have entered into a strategic partnership, with the purpose [...]

• Cancer research technology and kurma biofund to develop new antibody platform for translational research

  CANCER RESEARCH TECHNOLOGY, the commercial arm of Cancer Research UK, and Parisbased venture capital firm, Kurma [...]

• Idinvest Partners et Kurma Partners annoncent la cession de Prosensa

  BioMarin et Prosensa ont annoncé lundi 24 novembre matin l’intention pour de la société américaine d’acquérir 100% des actions de Prosensa [...]

• Idinvest Partners and Kurma Life Sciences Partners announce the IPO of Zealand Pharma A /S

  On Tuesday November 23rd, Zealand Pharma A/S (Zealand Pharma)initiated its first trading day on the Nasdaq OMX Copenhagen exchange. [...]

• Natixis Private Equity and CDC Entreprises announce the launching of Kurma Biofund

  Natixis Private Equity et CDC Entreprises lancent le premier fonds dédié aux secteurs des sciences de la vie à être né d’un partenariat stratégique [...]

• Kurma announces a consulting agreement with IDinvest Partners

  The agreement concerns a portion of the Biotech portfolio managed by IDInvest Partners, representing 87 million Euros invested. [...]

• Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S.

  Zealand Pharma (“Zealand” or the "Company") announces that it has today filed a Form F-1 Registration Statement for a proposed initial public offering of American Depositary Shares ("ADSs"). The Registration Statement relating to these securities has been filed with the U.S. Securities and Excha ...

• Total number of shares and voting rights in Zealand at June 30, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to state the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. [...]

• Zealand reports that Sanofi announces Soliqua™ 100/33 now available in the U.S

  Zealand Pharma (Zealand) reports that Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults   [...]

• Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome

  Zealand Pharma A/S (“Zealand”) announces that the last patient has been dosed in a phase II proof-of-concept, dose-finding trial with glepaglutide1 for the treatment of short bowel syndrome (SBS). SBS is a serious condition involving intestinal function [...]

• EU approval of Suliqua™ triggers USD 10 million milestone payment to Zealand

  Zealand Pharma (Zealand) today announced a USD 10 million milestone payment following Sanofi’s announcement of European Commission (EC) marketing authorization in Europe for Suliqua™, the once-daily titratable [...] 

• Zealand reports Q4 2016 Lyxumia® royalty revenue

  Zealand receives royalty revenue of DKK 5.3 million / €0.7 million in Q4 2016 (and DKK 24.4 million / €3.3 million in full year 2016) from sales of Lyxumia® by Sanofi outside the United States. [...]

• Notice of the date of Zealand’s Annual General Meeting 2017 and of deadline for proposals for the agenda

  The deadline for submitting proposals to be included on the agenda for the Annual General Meeting is February 21, 2017. Proposals may be sent by email to agm@zealandpharma.com or by letter to Zealand Pharma A/S, Smedeland 36, 2600 Glostrup, Denmark, att.: Investor Relations. [...]

• Zealand Pharma convenes its Annual General Meeting 2017

  Zealand Pharma ("Zealand") convenes the Company's ordinary Annual General Meeting 2017 to be held on [...]

• Zealand hosts conference call on March 15 at 4 pm CET to present 2016 full-year results

  Zealand Pharma A/S (“Zealand”) (CVR no. 20 04 50 78) announces that it will be hosting a conference call on March 15, 2017 at 4 pm CET/10 am EDT following the announcement of its full-year results and Annual Report 2016. [...]

• Zealand announces full-year results in line with guidance and releases its Annual Report for 2016

  Zealand Pharma A/S (“Zealand”) (CVR No. 20 04 50 78) announces financial results in line with guidance and considerable progress for its product portfolio and business for the 12-month period from January 1 to December 31, 2016. [...]

• Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system

  Zealand Pharma ("Zealand") announces positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. Dasiglucagon is a glucagon analogue fully owned by Zealand [...]

• Total number of shares and voting rights in Zealand at May 31, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to state the total number of shares and voting rights in the company at the end of a calendar month during which there have been changes to its share capital. [...]

• Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association (ADA) indicate use for treatment of severe hypoglycemia

  Zealand Pharma ("Zealand") and lead scientist on the investigational side, Dr. Tim Heise of Profil Neuss, will today present elaborated data from the Phase 2 trial of dasiglucagon in patients with type 1 diabetes to treat insulin-induced hypoglycemia at [...]

• Zealand to present at two international healthcare investor conferences in June 2017

  Zealand announces that its President and CEO, Britt Meelby Jensen, and Executive Vice President and CFO, Mats Blom, will present the Company and host investor meetings at the following healthcare investor forums taking place in New York and London in June 2017 [...]

• Zealand to regain control of elsiglutide

  Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, has today returned elsiglutide for the treatment of chemotherapy-induced diarrhea to Zealand, thereby concluding the licence agreement between the companies. Elsiglutide is a novel GLP-2 [...]

• New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%

  Zealand Pharma’s ("Zealand") partner Sanofi announced today that Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml lowered mean blood sugar levels (HbA1c) by 1.09-2.41% after 30 weeks in adults with type 2 diabetes previously treated with 15-40 units of basa ...

• Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome

  Zealand Pharma ("Zealand") announces positive results from the Phase 2 trial of glepaglutide in adult patients with short bowel syndrome (SBS). Glepaglutide is a novel long-acting GLP-2 analogue invented and fully owned by Zealand. [...]

• French pathogens discovery biotechnology start –up, PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financi

  Founded in September 2010 by Professor Marc Eloit and Luc Boblet (PhD), PathoQuest SAS completed, on March 11th 2011, its first round of financing [...]

• KURMA Partners invests in OxThera, first investment of its fund Kurma Biofund II

  Kurma Partners, a key European player in the financing of Innovation in Healthcare and Biotechnology, announces its first investment [...]

• Kurma Biofund extends UK partnerships with UCL

  Kurma Biofund extends UK partnerships with UCL Business plc (London) and the Institute for Child Health (University College London) [...]

• Stevenage BioScience Catalyst and Kurma Life Sciences Partners Announce Collaboration to Stimulate Investment in Bioscience Companies

  Stevenage, UK, and Paris, France, March 21 2012 - Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation [...]

• Kurma Partners and Idinvest Partners launches Dynacure a new company specialized in rare neuromuscular diseases

  Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. [...]

• Asarina Pharma's phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint

  Asarina Pharma, a drug development company focusing on the development of a novel therapy for severe premenstrual symptoms, publishes the efficacy and safety data from the randomized, controlled trial involving a total of 120 women with PMDD, in Psychoneuroendocrinology. [...]

• Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

  First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia [...]

• DAMAE Medical raises €2 million to develop its lead product for non-invasive, in-depth imaging and characterization of the skin

  DAMAE Medical, a leading French medtech company, announces the closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors.

• DR CLAUDE NICAISE JOINS MINORYX THERAPEUTICS AS INDEPENDENT BOARD MEMBER

  Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that Dr Claude Nicaise has joined its board of directors as an independent member. [...]

• FeetMe announces the closing of a seed round

  FeetMe, a medical device company that produces smart and connected insoles for improved running, walking and gait analysis, today announced it has raised €  1.95 million in seed funding. [...]

• MINORYX THERAPEUTICS FURTHER STRENGTHENS ITS SCIENTIFIC ADVISORY BOARD (SAB)

  Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that, Dr. Patrick Aubourg, Dr. Marc Engelen, Dr. Florian Eichler and Dr. Gerald Raymond, four renowned clinical experts in X-ALD joined its scientific advisory board  [... ...

• MINORYX THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM THE US FDA FOR ITS LEAD CANDIDATE MIN- 102

  MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the EMA. [...]

• MINORYX THERAPEUTICS SUCCESSFULLY COMPLETES PHASE 1 CLINICAL TRIAL FOR LEAD CANDIDATE MIN-102

  MIN-102 was well-tolerated at much higher doses than those required for efficacy. MIN-102 exhibited linear pharmacokinetics and no food effects were observed. Blood brain barrier penetration and biomarkers confirm PPAR gamma [...]

• Dr Bastian Dehmel Appointed CMO of OxThera

  OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer. [...]

• Matthew Gantz Appointed CEO of Oxthera

  OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. [...]

• Strong acceleration in growth during Q1 2017

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing its first-quarter 2017 revenues. [...]

• Safe Orthopaedics reports its full-year results for 2016

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, has today reported its full-year results for 2016. [...]

• Strong growth momentum in Q2 2017: +37%

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing its second-quarter 2017 revenues. [...]

• Very strong revenue growth in Q3 2017: +63%

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing its revenues for the third quarter of 2017 and its cash position at September 30, 2017. [...]

• Safe Orthopaedics announces the commercial launch of a bone substitute for its Walnut cervical cage

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments, is announcing today the commercial launch in Europe of a bone substitute for its Walnut cage for cervical surgeries. [...]

• Safe Orthopaedics reports revenue growth of 10% in FY 2016*, with an acceleration in the fourth quarter

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, has today released its revenue figures for the fourth quarter of 2016 and the financial year ended December 31, 2016 [...]

• Monthly information regarding the total number of voting rights and shares comprising the Company’s share capital

  Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer [...]

• Safe Orthopaedics expands into Germany and appoints Jochen Esser as Head of Sales Germany

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing that it is expanding into Germany and has appointed Jochen Esser as Head of Sales Germany. [...]

• Safe Orthopaedics products listed by AP-HP Paris Hospitals

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing that its principal products for thoracolumbar spinal fusion have been listed by AP-HP [...]

• Safe Orthopaedics Offers New Technologies to Treat Traumatic Injuries Due to Osteoporosis or Bone Metastases

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, now offers a transverse connector designed to rigidify the stabilisation of posterior spinal osteosynthesis, as well as cement injectable� ...

• Pascale Davis, an internationally renowned expert on the spine market, joins Safe Orthopaedics as Global Head of Marketing

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing the appointment of Pascale Davis, an internationally renowned expert on the spine market, as Global Head of Market ...

• Safe Orthopaedics continues to improve its results in the first half of 2017

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, today announces its results for the first half of 2017. [...] 

• Safe Orthopaedics announces the forthcoming arrival of its new Chief Financial Officer and the strengthening of its sales team

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, is today announcing that its new Chief Financial Officer will join the Company by the end of November 2017 as a replacement [...]

• Sensome, formerly Instent, raises €4.7m to bring the world’s first connected stroke guidewire to patients

  Sensome’s first application of its AI-powered micro-sensor technology can detect the composition of the blockage in the brain during stroke treatment [...]

• Passing of Zealand Pharma A/S Extraordinary General Meeting on 31 July 2017

  Today, Zealand Pharma A/S (Zealand) (CVR-no. 20 04 50 78) held an extraordinary general meeting at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark. At the meeting, all proposals presented to the extraordinary general meeting were adopted [...]

• Zealand Pharma A/S prices its initial public offering of American Depositary Shares on The Nasdaq Global Select Market in the United States

  With reference to the company announcement no. 29/2017 dated August 1, 2017 regarding the filing of a Form F-1 registration statement, including a preliminary prospectus, and commencement of an initial public offering of American Depositary Shares [...]

• Zealand Pharma A/S exercises its authorization granted by its extraordinary general meeting held on July 31, 2017 in connection with its initial public offering of American Depositary Shares in the United States

  With reference to the company announcement no. 29/2017, dated August 1, 2017, Zealand Pharma A/S (“Zealand”) announces that Zealand's board of directors (the "Board") has in accordance with article 7A of Zealand's articles of association exercised an authorization [...]

• Zealand Pharma A/S files final prospectus on a Form F-1 registration statement in connection with the initial public offering of American Depositary Shares in the United States

  With reference to company announcements (i) no. 29/2017 dated August 1, 2017 regarding the filing of a preliminary prospectus on a Form F-1 registration statement and launch of an initial public offering of American Depositary Shares [...]

• Stabilization period begins

  With reference to company announcement no. 31/2017 dated August 9, 2017 regarding the pricing of the initial public offering of American Depositary Shares (the "ADSs") on the Nasdaq Global Select Market in the United States under the symbol [...]

• Overallotment option of 15% has been exercised

  With reference to company announcements no. (i) 29/2017 dated August 1, 2017 regarding the launch of an initial public offering of American Depositary Shares (the "ADSs") on the Nasdaq Global Select Market in the United States under the symbol "ZEAL" [...]

• Zealand Pharma A/S publishes a prospectus regarding admission to trading and official listing of 4,375,000 new shares on Nasdaq Copenhagen as part of its issue of American Depositary Shares listed on the Nasdaq Global Select Market in the United States

  With reference to company announcements (i) no. 29/2017 dated August 1, 2017 regarding launch of an initial public offering of American Depositary Shares (the "ADSs") on the Nasdaq Global Select Market in the United States under the symbol "ZEAL" [...]

• Phase 1 trials for two novel treatments of obesity and/or diabetes initiated by Zealand partner Boehringer Ingelheim

  Zealand Pharma A/S ("Zealand") reports that Boehringer Ingelheim has announced the initiation of two Phase 1 trials, the first with a glucagon/GLP-1 agonist that has the potential for once-weekly administration for the treatment of obesity [...]

• Completion of exercise in full of overallotment option of 15%

  With reference to the company announcements no. 37/2017, dated August 15, 2017 regarding the exercise in full of overallotment option of 15% by Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, Zealand Pharma A/S ("Zealand") [...]

• Zealand grants new warrants under employee warrant program

  Zealand announces the grant of warrants to the Company’s President and CEO Britt Meelby Jensen. The warrants are granted under the warrant program covered by the authority pursuant to Section 8.4 of Zealand’s Articles of Association [...]

• Interim report for the first half of 2017

  Zealand Pharma A/S (“Zealand”) (company reg. no. 20 04 50 78) announces financial results in line with guidance and continued positive progress for its product portfolio and business for the first half of 2017 [...]

• Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017

  Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the Morgan Stanley Global Healthcare Conference in New York, at the Grand Hyatt hotel on Wednesday, September 12, 2017 at 1 pm (EST). [...]

• Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL

  Sanofi has announced that in certain adults with type 2 diabetes, Soliqua® 100/33 (insulin glargine and lixisenatide injection, 100 units/mL and 33 mcg/mL) provided blood sugar control earlier and in more adults than those [...]

• Zealand and Orbit Discovery enter into research collaboration

  Zealand Pharma A/S ("Zealand") and Orbit Discovery Ltd (“Orbit”) announce that they have entered into a multi-target research collaboration to identify novel peptide therapeutics using Orbit’s proprietary peptide display technology [...]

• Zealand increases its share capital as a consequence of exercise of employee warrants

  Zealand has increased its share capital by a nominal amount of DKK 28,675 divided into 28,675 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee [...]

• Zealand Pharma and Torrey Pines Institute for Molecular Studies announce research collaboration

  Zealand Pharma A/S ("Zealand") and Torrey Pines Institute for Molecular Studies (TPIMS) announce that they have entered into a multi-target research collaboration to identify novel peptide therapeutics using TPIMS’s proprietary [...]

• Total number of shares and voting rights in Zealand at September 30, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month [...]

• Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

  Zealand Pharma announces dosing has started in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of SBS. [...]

• Kurma Partners invests in Cardiologs

  We are pleased to announce the $6.4 million financing of Cardiologs Technologies. Cardiologs uses image recognition and deep learning to analyze an ECG and ambitions to bring deeper analysis and information to cardiologists. With its solution, Cardiologs will bring cardiology to the next level. [.. ...

• Kurma Partners is pursuing the implementation of its investment strategy in innovation to create Biotech companies

  Kurma Partners, a European venture capital company specialized in Life Sciences, announced today the closing of the first (Series A) €20 million financing round of ImCheck Therapeutics, a company created according to Kurma’s investment model in innovation. [...]

• Kurma Partners invests in Feetme

  Kurma Partners led a €1.95 million Seed financing of FeetMe with Idinvest Partners, Paris Saclay Seed Fund and Seventure. Existing investor SOS Ventures also participated in the round. Alain Horvais, Partner at Kurma will join the board of directors of the company. [...]

• Kurma Partners announces a new Investment in Horama S.A.

  Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces a new investment of Kurma Biofund II. [...]

• Horama raises €19 million in a Series B financing round

  Horama raises 19 million euros from new investors (Kurma Partners, Fund+, Pontifax and Idinvest) and existing investors (Omnes Capital, GO Capital and Sham Innovation Santé/Turenne) to fund the development of gene therapy treatments for rare retinal diseases [...]

• Ionis Licenses Novel Antisense Drug For The Treatment Of Centronuclear Myopathy To Dynacure

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure ...

• Kurma Partners announces the successful IPO of Orphazyme.

  Kurma Partners announces the successful IPO of Orphazyme, a leading company in rare diseases which raises €80M on Nasdaq Copenhagen [....]

• Step Pharma Completes €14.5 million Series A Financing with Additional New Investor

  Step Pharma today announced the closing of a Series A financing totalling €14.5 million. Pontifax joined existing investors led by Kurma Partners, and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares), Inserm Transfert Initiative, Idinvest, Sygnature Discovery [....]

• Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has resumed patient enrollment in the TACTT3 [....]

• Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has added a third clinical-stage development program [....]

• Auris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow

  Auris Medical Holding AG(NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide a business update tomorrow [....]

• Auris Medical Announces Pricing of $10 Million Public Offering

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the pricing of its previously announced public offering [...]

• Auris Medical Announces Proposed Public Offering of Common Shares and Warrants

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it is offering to sell common shares and warrants [...]

• Auris Medical and King's College London Extend Tinnitus Collaboration

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King's College London [...]

• Auris Medical Announces Closing of $10 Million Public Offering

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the closing of its previously announced public offering [...]

• Auris Medical to Present at the 29th Annual Roth Conference on March 14

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced thatThomas Meyer, Ph.D., Chairman and Chief Executive Officer [...]

• Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that theUS Food and Drug Administration(FDA) has granted [...]

• Auris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the full year 2016 [...]

• Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced thatThomas Meyer, Ph.D., Chairman and Chief Executive Officer [...]

• Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the full year [...]

• Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand’s long-acting GLP-2 analog glepaglutide

  Zealand Pharma announces that all subjects have been enrolled and dosed in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Following positive results from a Phase 2 trial in June 2017 indicating a longer than exp ...

• Zealand reports royalty revenue for the third quarter of 2017

  Zealand Pharma (“Zealand”) reports Q3 2017 royalty revenue from Sanofi’s sales of Lyxumia®/Adlyxin® (lixisenatide) of DKK 5.0 million/USD 0.8 million and from Suliqua®/Soliqua® 100/33 of DKK 5.4 million/USD 0.9 million [...]

• Zealand Pharma will attend the Jefferies Healthcare Conference in London and the Bryan Garnier & Co Healthcare Conference in Paris, both in November

  Mats Blom, Executive Vice President and Chief Financial Officer of Zealand Pharma, will be attending the Jefferies Healthcare Conference, London, on Wednesday, November 15, 2017. Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will be attending the Bryan Garnier & ...

• Interim report for the first nine months of 2017

  Zealand Pharma A/S (“ZEAL”) announces financial results and continued strong progress for its product candidates and business for the first nine months of 2017. Financial guidance for 2017 has been revised with 4-6% lower operating expenses. [...]

• Zealand increases its share capital as a consequence of exercise of employee warrants

  Zealand has increased its share capital by a nominal amount of DKK 2,500 divided into 2,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted [...]

• Zealand Pharma to attend three U.S healthcare conferences in December

  Britt Meelby Jensen, President and Chief Executive Officer (CEO) and Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be present at the Carnegie Nordic Healthcare Day, New York

• Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

  Zealand Pharma A/S ("Zealand") announces the initiation of the second Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of severe hypoglycemia in patients with Type 1 Diabetes (T1DM). [...]

• Financial calendar for Zealand Pharma in 2018

  Zealand Pharma A/S (“ZEAL”) announces the following dates for the company's planned financial reporting in 2018 [...]

• Total number of shares and voting rights in Zealand at November 30, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. [...]

• Employee elected board member change in Zealand Pharma

  Zealand Pharma A/S (“ZEAL”) announces that Rasmus Just, Director of Business Development and employee-elected Board Member, leaves the company effective from 1 December 2017. [...]

• Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced key results from AMPACT2 (AM-101 in thePost-Acute Treatment [...]

• Auris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that onMarch 30, 2017, the Company received a letter from [...]

• Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the first [...]

• Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the first quarter [...]

• Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced key results from AMPACT1 (AM-101 in thePost-Acute Treatment [...]

• Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that the company will host a scientific symposium on acute hearing [...]

• Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced that it will host a Key Opinion Leader event onFriday, [...]

• Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the second quarter [...]

• Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has completed patient enrollment in the Phase 3 [...]

• Auris Medical Completes Acquisition of AM-125 Assets

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important, unmet medical needs in otolaryngology, today announced that it has completed its acquisition of various assets [...]

• Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that the company will host a scientific symposium [...]

• Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the second [...]

• Auris Medical Announces Receipt of Nasdaq Notice

  Auris Medical Holding AG("the Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that onAugust 18, 2017 [...]

• Auris Medical Announces Transfer to Nasdaq Capital Market

  Auris Medical Holding AG(the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today the approval of the Company's request to [...]

• Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced thatThomas Meyer, Ph.D., Chairman [...]

• Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has completed the recruitment [...]

• Auris Medical to Report Third Quarter 2017 Financial Results and Provide Business Update on Tuesday, November 28, 2017

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide a business update [...]

• Auris Medical Provides Board of Directors Update

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today the resignation ofAntoine Papiernikas a member [...]

• Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today the execution of two share purchase agreements for [...]

• Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced financial results for the third quarter ended September [...]

• Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

  Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced top-line results from the HEALOS Phase 3 clinical trial [...]

• Ionis licenses novel antisense drug for the treatment of centronuclear myopathy to Dynacure

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx(Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license [...]

• Dynacure joins ongoing Natural History Study in Centronuclear Myopathies with the Institute of Myology

  Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM), a debilitating rare disease affecting children and young adults. [...]

• IMCHECK THERAPEUTICS OBTAINS 1M€ FROM BPIFRANCE TO CONTRIBUTE TO THE DEVELOPMENT OF A NOVEL THERAPEUTIC ANTIBODY IN IMMUNO-ONCOLOGY

  ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announces a funding award of €930,000 from Bpifrance to contribute to the advancement of one of its novel immunotherapy program in cancer. ...

• IMCHECK THERAPEUTICS RAISES €20 MILLION AND APPOINTS ITS CEO

  ImCheck Therapeutics, an emerging player in the field of cancer and auto-immunity, today announced the completion of a €20 Million Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest and joined by Gimv [...]

• ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA

  Orphazyme A/S ("Orphazyme" or the "Company"), a Danish biotech company with a late stage orphan drug pipeline, today announced that the U.S. Food and Drug Administration (“FDA”), Office of Orphan Products Development, has granted an orphan drug designation to [...]

• ORPHAZYME RAISES EUR 14 MILLION TO FURTHER EXPAND ITS CLINICAL DEVELOPMENT PROGRAMME

  Orphazyme ApS today announced the successful completion of a EUR 14M financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Kurma Partners, Idinvest Partners, Novo A/S, Sunstone Capital and Aescap Venture. [...]

• ORPHAZYME COMPLETES ENROLMENT OF PATIENTS FOR PHASE 3 CLINICAL TRIAL IN NIEMANN-PICK TYPE C DISEASE

  Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, today announced the completion of enrolment for its lead program within Niemann-Pick type C disease. [...]

• OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

  OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical [...]

• Matthew Gantz Appointed CEO of Oxthera

  OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. [...]

• François-Henri Reynaud appointed as Safe Orthopaedics’ Chief Financial Officer

  SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, today announces the appointment of François-Henri Reynaud as Chief Financial and Administrative Officer. [...]

• Talix and Geisinger Health Plan to Present on Data Analytics for Risk Adjustment at 2017 RISE Nashville Summit

  Talix, Inc., a premier provider of risk analytics solutions for value-based care, today announced that Shahyan Currimbhoy, senior vice president of product management and engineering at Talix, and Karena Weikel, ASA, FAHM, CSFS, vice president of risk and revenue management [...]

• Talix Introduces Commercial Risk Adjustment Support for Providers and Health Plans

  Talix, Inc., a leading provider of risk analytics solutions for value-based care, today announced its Coding InSight application now supports risk adjustment for health plans and providers participating in commercial programs such as the Affordable Care Act (ACA) health [...]

• Talix Achieves HITRUST CSF Certification to Further Mitigate Risk in Third Party Privacy, Security and Compliance

  Talix, Inc., a premier provider of healthcare risk adjustment and quality solutions for value-based care, today announced its Coding InSight platform and Health Risk Assessment (HRA) application have earned Certified status for information security by the Health Information Trust [...]

• Health First Health Plans and Talix to Present on Risk Adjustment Compliance Strategies at 2017 RISE West Summit

  Talix, Inc., a premier provider of healthcare risk adjustment and quality analytics solutions, today announced it will partner with Florida-based Health First Health Plans to present a session on using analytics to improve coding compliance and reduce audit risk at the 2017 RISE West Summit. [... ...

• Nuance and Talix Team to Improve Care Quality and Risk Adjustment at the Point of Decision Making

  Nuance Communications, Inc. and Talix, Inc. today announced a reseller agreement to deliver a new patient-focused solution to support better outcomes and risk adjustment through decision support and automation. [...]

• Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

  Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financing round. The round involved a syndicate of leading international life sciences investors led [...]

• Gene Therapy of Liver Diseases

  In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases. [...]

• Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation.

  Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, [...]

• FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies.

  Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug [...]

• Xeltis’ Technology for Natural Heart Valve Restoration Featured as the Future of Valve Therapy at EuroPCR

  Dedicated plenary session on Endogenous Tissue Restoration (ETR) previews first data from aortic valve preclinical studies [...]

• Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs

  Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million [...]

• Zealand increases its share capital as a consequence of exercise of employee warrants

  Zealand has increased its share capital by a nominal amount of DKK 1,500 divided into 1,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted [...]

• Total number of shares and voting rights in Zealand at August 31, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements regarding the total number of shares and voting rights in the Company at the end [...]

• Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017

  Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the Morgan Stanley Global Healthcare Conference in New York, at the Grand Hyatt hotel on Wednesday, September 12, 2017 [...]

• Zealand and Orbit Discovery enter into research collaboration

  Zealand Pharma A/S ("Zealand") and Orbit Discovery Ltd (“Orbit”) announce that they have entered into a multi-target research collaboration to identify novel peptide therapeutics using Orbit’s proprietary peptide display technology. [...]

• Zealand increases its share capital as a consequence of exercise of employee warrants

  Zealand has increased its share capital by a nominal amount of DKK 28,675 divided into 28,675 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one [...]

• Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL

  Sanofi has announced that in certain adults with type 2 diabetes, Soliqua® 100/33 (insulin glargine and lixisenatide injection, 100 units/mL and 33 mcg/mL) provided blood sugar control earlier and in more adults than those treated with insulin glargine 100 units/mL alone, according to [...]

• Zealand Pharma and Torrey Pines Institute for Molecular Studies announce research collaboration

  Zealand Pharma A/S ("Zealand") and Torrey Pines Institute for Molecular Studies (TPIMS) announce that they have entered into a multitarget research collaboration to identify novel peptide therapeutics using TPIMS’s proprietary peptide libraries. Through this partnership, TPIMS will provide Zealand ...

• Total number of shares and voting rights in Zealand at September 30, 2017

  In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. [...]

• Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

  Zealand Pharma announces dosing has started in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of SBS. [...]

• U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

  The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS)*. Glepaglutide is a Zealandinvented long-acting GLP-2 analog that may offer a [...]

• Kurma Partners announces that QIAGEN enters into agreement to acquire STAT

  January 31, 2018 – Kurma Partners announced today that Qiagen entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step [...]

• Oxthera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

  Oxthera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces [...]

• Belinda Cowling (PhD) joins Dynacure as Head of Research

  Belinda will be responsible for the company’s R&D strategy, lead Dynacure’s research programs in centronuclear myopathy and other disease domains. She will focus on translational research, drug-candidate development and expand Dynacure’s research network with academic and industrial organizati ...

• Safe Orthopaedics annonce ses résultats 2017 et son Chiffre d’affaires du premier trimestre 2018

  2017 aura marqué un tournant pour Safe Orthopaedics. Au-delà du renforcement de l’équipe commerciale focalisée stratégiquement sur le segment de la fracture vertébrale, nous avons amélioré sensiblement nos performances financières tout en délivrant notre meilleure croissance an ...

• New cross-border Board reflects global potential of therapy

  Asarina Pharma’s new Board reflects the global potential of its first-in-class therapy for PMDD. New members include senior pharma, science and research professionals from a range of countries contributing a powerful mix of skills. [...]

• ImCheck Therapeutics appoints Dr. Debasish Roychowdhury as its independent Chairman of the Board

  With over a decade of patient care as a hematologist/oncologist and a career as a big pharma senior executive in R&D, regulatory and commercial operations, Dr. Roychowdhury is a recognized leader in the pharmaceutical industry & oncology product development. [...]

• Kurma Partners announces the first closing of Kurma Biofund III

  Kurma Partners, a leading European venture capital firm in early stage Life Sciences based in Paris, announced today that it has completed the first closing of its third Biofund, Kurma Biofund III, with a target for the final closing of €150m. Kurma Biofund III is backed by cornerstone investors i ...

• Minoryx Therapeutics extends its activities in Belgium

  Minoryx Therapeutics opens Belgian subsidiary that will lead important development activities [...]

• Asceneuron appoints Peter Van Vlasselaer as Chairman

  Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors. [...]

• Kurma Partners sees great opportunities for early-stage biotech investments in Germany and launches operations in Munich

  After a successful First Closing of Kurma‘s new Biofund III at the end of last year, the Venture Capital firm today announced the launch of its Munich operations headed by newly appointed partner Dr. Peter Neubeck. Founded in 2009, Kurma Partners invests in innovation in healthcare and biotechnolo ...

• Safe Orthopaedics

  Safe Orthopaedics (FR0012452746 – SAFOR), a company specialized in the design and marketing of single-use implants and instruments improving the minimally invasive treatment of spinal fracture conditions, is today announcing its revenues for the fourth quarter of 2018 and for the 2018 financial ye ...

• Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to launch a phase 2 clinical trial in Friedreich’s Ataxia with its lead candidate, MIN-10 ...

• PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS

  Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease [...]

• Asarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects

  Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects [...]

• Kurma Partners announces the completion of $38.5 Million Series B financing of DNA Script

  DNA Script today announced an oversubscribed Series B fundraising of $38.5M led by LSP, one of Europe’s largest and most experienced healthcare investment firms. BPIFrance joined the round, alongside existing investors Kurma Partners, Idinvest Partners Illumina Ventures, M Ventures and Sofinnova P ...

• Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’

  Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for DYN101 [...]

• Safe Orthopaedics annonce la certification de SteriSpineTM PS au Japon

  Safe Orthopaedics, société spécialisée dans la conception et la commercialisation d'implants et d'instruments à usage unique améliorant le traitement mini-invasif des pathologies de la fracture du rachis, annonce l'enregistrement du SteriSpineTM PS au Japon [...]

• Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN- 102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia. [...]

• Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

  Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has received constructive advice from the European Medicines Agency (EMA)’s Scientific Advice Working Group in response to the request fo ...

• AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

  AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today announces that it has raised €116m [$133m] from a ...

• Sepranolone receives FDA IND approval in menstrual migraine

  Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile. [...]

• Safe Orthopaedics annonce son chiffre d’affaires du 1er semestre 2019 et le lancement de SteriSpine PS Gen 2

  Safe Orthopaedics (FR0012452746 – SAFOR),société spécialisée dans la conception et la commercialisation d’implants et d’instruments à usageunique améliorant le traitement mini-invasif des pathologies de la fracture du rachis, annonceaujourd’hui son chiffre d’affaires semestriel cl ...

• Genmab and BliNK Biomedical Enter into Commercial License Agreement

  Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into an agreement with BliNK Biomedical for an exclusive commercial license to certain antibodies targeting CD47, for potential development and commercialization into novel bispecific therapeutics created via Genmab’s propriet ...

• Orphazyme appoints Kim Stratton as Chief Executive Officer

  Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim S ...

• Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis

  Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has completed enrollment in its phase 3 trial evaluating arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS) ahead of sche ...

• ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer

  ImCheck Therapeutics, a biotech company on the cutting edge of the next wave of immunotherapies against cancer and autoimmune diseases, announced today the appointment of Paul Frohna MD, PhD, PharmD as its Chief Medical Officer, a newly created position. Dr. Frohna is a physician-scientist with over ...

• Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

  Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has had a positive meeting with the FDA and remains on track to submit an NDA for arimoclomol for NPC in H1 2020. [...]

• Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

  Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases. [...]

• ImCheck Therapeutics Awarded €2 Million from Bpifrance

  ImCheck Therapeutics, a biotech company on the cutting edge of the next wave of immunotherapies against cancer and autoimmune diseases, announced the award of €2 million from Bpifrance to contribute to the development of its most advanced novel cancer immunotherapy program. With this additional fi ...

• Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’

  Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate t ...

• First patient included in menstrual migraine study

  Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020. [...]

• PathoQuest Secures 8 Million Euros in New Financing

  PathoQuest, a genomic expert company dedicated to the microbiology testing market and a leader in clinical diagnostics and biologics testing applications, today announces the closing of an 8M euros financing series. The funding includes a venture loan from Norgine Ventures, financing from historical ...

• Step Pharma Appoints Seasoned Drug Developer Dr. Andrew Parker as Chief Executive Officer

  Paris, France, 6 September 2019 – Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D., as Chief Executive Officer and member of the Supervisory Board. Dr. Parker joins Step Pharma with more than 20 years’ experien ...

• Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema

  Pharvaris has initiated its first-in-human clinical trial of PHA121. Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners [...]

• Ermium Therapeutics completes Series A funding of €6.3 million to develop breakthrough auto-immune therapeutics.

  Ermium Therapeutics a Paris-based biotech company developing innovative health products for auto-immune and inflammatory diseases announced today a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.

• Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment

  Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and ...

• Safe Orthopaedics annonce un chiffre d’affaires record au T3 2019 : 1 159k€, en croissance de +41%

  Safe Orthopaedics (FR0012452746 – ALSAF), société spécialisée dans la conception et la commercialisation d’implants et d’instruments à usage unique améliorant le traitement mini-invasif des pathologies de la fracture du rachis, annonce aujourd’hui son chiffre d’affaires trimestriel c ...

• Safe Orthopaedics publie ses résultats du 1er semestre 2019

  Safe Orthopaedics (FR0012452746 – SAFOR), société spécialisée dans la conception et la commercialisation d’implants et d’instruments à usage unique améliorant le traitement mini-invasif des pathologies de la fracture du rachis, annonce aujourd’hui son chiffre d’affaires semestriel cl ...

• Via Munich office, Kurma launches oncology company Tacalyx

  Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this year with the intention of creating start-u ...

• Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

  Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Fri ...

• Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

  Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its lead drug candidate, leriglitazone (MIN-102), has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and D ...

• FeetMe, the Leading Provider of Real-World Setting Gait Assessment and Rehabilitation Solutions, Annonces the Closing of a Series A Round to Develop New Digital Health Services and Accelerate Its Commercial Activities

  FeetMe, a medical device company that produces smart medical wearables and digital health services to improve mobility, today announced it has raised €9.4M in Series A funding [...]

• Asarina Pharma has completed a directed share issue of approximately SEK 48 million

  Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces that the Company has successfully completed a directed share issue of 2,159,148 shares, corresponding to approximately SEK 48 million. In addition, existing shareholders have ...

• Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

  Mataró, Barcelona, Spain and Charleroi, Belgium, November 12, 2019 – Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its lead drug candidate, leriglitazone (MIN-102), has been grant ...

• Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)

  Copenhagen, Denmark, November 19, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclo ...

• ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

  Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ) T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, ann ...

• First patient dosed in landmark Menstrual Migraine study

  Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine. [...]

• Samyang Biopharm USA, Inc. and Talix Therapeutics NV Announce Global Strategic Collaboration to Advance Novel Immuno-Oncology Therapeutic

  Samyang Biopharm USA, Inc. a global biotech subsidiary of the Samyang Pharmaceuticals Corp. , announced today that the company has entered into a research collaboration with the exclusive option to a worldwide licensing agreement with Talix Therapeutics NV. Financial terms of the agreement were not ...

• Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C

  Copenhagen, Denmark, January 3, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces 12- month interim data from an open-label extension of a phase 2/3 study of arimoclomol, an in ...

• Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

  Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selectivePPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for b ...

• PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service

  PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility re ...

• Sensome Raises $9 Million B Round with Equity Investment from Asahi Intecc

  The two companies start development program to integrate Sensome’s tissue micro-sensor into Asahi’s world class guidewire [...]

• Cardiologs Raises $15 Million in Series A Funding Led by Alven

  Funding will accelerate adopon of the company’s breakthrough AI-based heart disease diagnosc soluon by supporng physicians with unprecedented EKG data analysis and reporng capabilies [...]

• Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement and raises approximately DKK 745,000,000 (EUR 100 million/USD 110 million)

  Copenhagen, Denmark, February 7, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the completion of an offering of 7,032,937 new shares and existing shares in a directed issue ...

• Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies

  Bayer and Meiogenix, a biotech company focused on next-generation breeding technologies, announced today a collaboration to advance agricultural research and development by accelerating the development of Meiogenix’s proprietary technologies related to plant breeding and genome editing application ...

• Xeltis trials show promising function of living heart valves restored in children

  Eindhoven (NL)/Zurich (CH), 14th February 2020 - Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves developed in patients as a result of its restorative implants. The recent trial data have been presented today at the International Conference of T ...

• Asarina Pharma AB (publ) Year-end 2019 Report released

  Asarina Pharma AB today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a direct ...

• Dynacure Announces First Patient Dosed in Phase 1 / 2 'UNITE-CNM' Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)

  STRASBOURG, France and PHILADELPHIA, March 5, 2020 /PRNewswire/ -- Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the first patient has been dosed with DYN101 in a Phase 1 / 2 study called 'Unite-CNM ...

• AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

  Utrecht, The Netherlands, 31 March 2020 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP), today announce ...

• Dynacure Announces €50M ($55M) Series C Financing

  STRASBOURG, France and PHILADELPHIA, April 2, 2020 /PRNewswire/ -- Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a €50 million Series C financing led by Perceptive Advisors. [...]

• Asarina Pharma Annual Report for 2019 released

  Asarina Pharma AB today announces that its Annual Report for 2019 is now available on the company’s website [...]

• ANNUAL REPORT 2019

  About Asarina Pharma. We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like P ...

• Kurma Partners announces the final closing of its Kurma Biofund III fund at €160 million

  Validation of Kurma Partners’ business model with the closing of its third fund dedicated to Life Sciences for a significantly larger amount than its two first funds, Kurma Biofund I (€51m) and Kurma Biofund II (€55m) [...]

• Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis

  Copenhagen, Denmark, May 22, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company has received Fast Track Designation from the US Food and Drug Administration (FDA) for ...

• Alizé Pharma 3 change de nom pour Amolyt Pharma, illustrant sa stratégie de développement d’un portefeuille de peptides thérapeutiques pour les maladies endocriniennes et métaboliques rares

  LYON, France et NEWTON, Mass., 02 juin 2020 (GLOBE NEWSWIRE) -- Alizé Pharma 3, une société internationale spécialisée dans le développement de peptides thérapeutiques pour le traitement de maladies endocriniennes et métaboliques rares, annonce aujourd’hui qu’elle change de nom pour Amol ...

• Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.

  PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cho ...

• Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers

  Copenhagen, Denmark, June 24, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces topline results from a 6-month phase 2 dose-finding study in Gaucher disease wi ...

• DeepUll closes Series A Financing to improve early diagnosis of sepsis

  Barcelona, 7 July 2020.- DeepUll announced today the closing of a 3.5 million Euro round Series A financing led by Kurma Partners and with participation from Alta Life Sciences, Axis Participaciones Empresariales, and Sofimac Innovation, through its new investment fund Pertinence Invest 2 advised b ...

• Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

  Copenhagen, Denmark, July 20, 2020 - Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has completed the ...

• €27 mln voor nieuw biotechbedrijf Vico

  Het biotechbedrijf Vico Therapeutics dat vorig jaar is opgericht, heeft €27 mln aan startkapitaal opgehaald. Dat geldt als een hoog bedrag voor een ontwikkelaar van nieuwe medicijnen. Het bedrijf uit Leiden heeft relatief veel geld nodig, omdat het zijn eerste middel volgend jaar al op mensen h ...

• DNA Script Expands Series B to $89M

  Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ - the world’s first enzymatic DNA printer. PARIS and SOUTH SAN FRANCISCO, Calif. | July 29, 2020 DNA Script today announced a $50 million extension to its Series B financing, bringing ...

• Dynacure Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for DYN101 for Myotubular and Centronuclear Myopathies (CNM)

  STRASBOURG, France and PHILADELPHIA, July 30, 2020 /PRNewswire/ -- Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease design ...

• Asarina Pharma AB (publ) Interim Report Q2 2020 released ​​​​​​

  Asarina Pharma CEO Peter Nordkild: “The second Quarter 2020 has given us continued proof of the urgent need for new, safe and effective treatments for the devastating conditions that our flagship compound, Sepranolone, targets. Despite disappointing results in our Phase IIb PMDD study at the b ...

• Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C

  If approved, arimoclomol would become the first approved therapy in the U.S. for people with Niemann-Pick disease Type C (NPC) FDA has set target PDUFA action date of March 17, 2021 Copenhagen, Denmark, September 16, 2020 - Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company ...

• Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

  • Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition • Minoryx will receive an upfront and milestone payments of up to $78 million, as well as doub ...

• Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

  PARIS, France and NEW YORK, N.Y. - September 23, 2020 - Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that they have en ...

• Kurma Partners announces the first closing of Kurma Diagnostics 2 (KDx2) fund at €50 million

  • Kurma Diagnostics is currently the only investment fund wholly dedicated to financing early-stage European innovative medical diagnostic companies • KDx2 will finance 15 Deeptech companies specialized in the development of disruptive molecular diagnostic tools, smart and connected diagn ...

• Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe

  • As announced on September 21, 2020, Orphazyme commenced an initial public offering of American Depositary Shares (“ADSs”) in the United States, and commenced a concurrent private placement of ordinary shares in Europe ▪ Today, September 29, 2020 (CET), Orphazyme announces the ...

• Full patient enrolment in Phase IIa Menstrual Migraine study

  Asarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested ...

• PathoQuest obtains Pharmaceutical Establishment status from French ANSM for its biological drug testing activities

  Paris, France - September 29, 2020 - PathoQuest, a leader in quality control solutions based on the company’s expertise and use of cutting-edge genomic sequencing technology, announced that it has obtained the administrative authorization of Pharmaceutical Establishment from the French Agence ...

• Corlieve Therapeutics SAS closes seed financing to develop therapies for severe neurological conditions

  Corlieve Therapeutics today announced the closing of its seed financing led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures. Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve’s lead program employs a novel AAV gene the ...

• European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

  • EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs • Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist • Venture debt operation supported by the Investment Plan ...

• Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

  LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) - Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed. ...

• Kurma Partners strengthens its teams and promotes its talents

  • Benjamin Belot joined Kurma as Partner to add its experience in digital health to the team • Hadrien Bouchez and Amine Marouf are promoted to Principals to acknowledge their contribution to the development of the firm   Kurma Partners, a leading European venture capital compa ...

• Charles River and PathoQuest Strengthen Strategic Partnership

  PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory in Wayne, PA to expand its next-generation sequencing capabilities November 12, 2020 08:00 AM Eastern Standard Time - WILMINGTON, Mass. & PARIS - (BUSINESS WIRE) - PathoQuest SAS, a genomic exp ...

• Synendos Therapeutics Raises CHF 20 Million in Series A Financing

  • Breakthrough approach to developing safe and effective therapies for unmet needs in neuropsychiatric disorders • Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study • Supported by s ...

• Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE

  PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 - Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-rec ...

• Lucine lève 5,5 millions d’euros pour développer une thérapie digitale et ainsi soulager et traiter les malades de pathologies chroniques

  Paris, le 18 novembre 2020, La startup bordelaise Lucine réalise une levée de fonds de 5,5 millions d’euros auprès de Kurma Partners, Bpifrance via son fonds Patient Autonome, BNP Paribas Développement, Aquiti Gestion et Irdi Soridec pour financer le développ ...

• Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

  PARIS, France and NEW YORK, N.Y. - November 18, 2020 - Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food ...

• Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE

  • New investors include Viking Global Investors, General Atlantic, and Cormorant Asset Management, with an expanded position by Venrock Healthcare Capital Partners • Phase 2 study of PHVS416 expected to initiate in 2021 Zug, Switzerland, Nov. 18, 2020 - Pharvaris, a clinical-stage co ...

• Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

  Preclinical data highlights potential therapeutic action and protection against neurodegeneration Mataró, Barcelona, Spain and Gosselies, Belgium, November 16, 2020 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment opti ...

• Asarina Pharma AB (publ) Q3 2020 report released

  Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. ...

• Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing

  Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany - Marseille, France, 25 November 2020. Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need ...

• Amolyt Pharma annonce une collaboration de recherche avec PeptiDream

  Amolyt Pharma et PeptiDream collaboreront pour optimiser et évaluer des antagonistes du récepteur de l’hormone de croissance (GHRA) afin de sélectionner un candidat-médicament en vue d’un développment clinique comme traitement potentiel de l'acrom&e ...

• Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich's ataxia

  Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting in clinical benefit in this orphan disease Mataró, Barcelona, Spain, December 15, 2020 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating ...

• Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

  Lyon, France, and Cambridge, MA, January 6, 2021 - Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the com ...

• AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

  • First patients with COVID-19 enrolled in the REVIVAL Phase III study • COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall • RVO, an agency of the ...

• IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

  Copenhagen, Denmark - January 13, 2021: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round wa ...

• Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

  Largest prospective efficacy study conducted in the orphan disease AMN Leriglitazone significantly reduces progression of cerebral lesions and myelopathy symptoms Minoryx preparing for discussions with regulators for approval of leriglitazone for AMN patients Mataró, Barcelona, ...

• MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

    MedLumics’ oversubscribed financing round closes at EUR 18M to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation MedTech veteran, Rich Ferrari, joins MedLumics’ Board of Directors as new Chairman Madrid, Spain ...

• New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome

  (Stockholm, 11 February 2021.) Two sets of new preclinical data presented by Prof Marco Bortolato (Univ. of Utah) confirm that Sepranolone suppresses tics in Tourette Syndrome (TS) and restores Prepulse Inhibition (PPI), a key phenomenon related to TS with no observable side-effects. The new data al ...

• Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur

    Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe&r ...

• Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

  Award will fund first in human clinical trials of next generation O-GlcNAcase inhibitor, ASN51, to start Q2 2021 Lausanne, SWITZERLAND and San Francisco, CA, USA, 9 March, 2021 - Asceneuron SA, an emerging leader in the development of treatments for neurodegenerative diseases, announced today t ...

• Asarina Pharma AB (publ) Annual Report 2020 released

  Asarina Pharma CEO Peter Nordkild: “2020 and early 2021 have seen new research and additional data confirming and consolidating the efficacy and potential of our flagship compound Sepranolone. As we continue forward into an eventful 2021, we remain confident of the significant clinical relevan ...

• Mila lance une étude clinique à échelle internationale sur les bénéfices du rythme pour les enfants atteints des troubles spécifiques des apprentissages et du langage

  Soutenue par Kurma Partners, BNP Paribas Développement et Bpifrance via son fonds Patient Autonome, la jeune entreprise va valider cliniquement sa solution pour améliorer le quotidien des patients et le suivi thérapeutique des professionnels de santé Paris, le 17 mar ...

• Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies

  Archamps, France, 24th March 2021 – Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joini ...

• Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

  Mirum expands potential opportunities across rare disease pipeline Vivet to lead preclinical development of its two gene therapy programs for PFIC3 and PFIC2 Mirum gains option to license VTX-803 and VTX-802 FOSTER CITY, Calif. and PARIS, France - March 12, 2021 - Mirum Pharmaceuticals ...

• Arkhn raises €4 million to lead healthcare institutions towards sovereign and efficient data management

    Newfund and Kurma Partners led this first round of financing. The funds raised will support Arkhn's strong growth and the deployment of its data architecture solutions in France and Europe. Data interoperability is critical to improve care, support research, and make hospitals m ...

• Asarina Pharma receives approval of CTA for phase IIa Tourette study

  Stockholm, 19 May, 2021 - Asarina Pharma’s Clinical Trial Application for a phase IIa study with Sepranolone in Tourette Syndrome has been approved by the Danish Medical Agency, with the study to commence in August 2021 at two sites in Denmark. With Cognitive Behavioral Therapy as firs ...

• SmartCatch raises EUR 3.2 Million in Seed financing to accelerate the development of its flagship solution in liquid biopsy

  KURMA Partners, IRDI Capital Investissement and M-Capital have acquired a stake in SmartCatch, a French medtech and deeptech company specialized in the development of cutting-edge diagnostic tools for precision medicine. The capital operation aims to accelerate the company's growth and the devel ...

• Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

  Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases Mataró, Barcelona, Spain, June 3, 2021 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating ...

• Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

  Stockholm, 8 June 2021 - The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in ...

• Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies

  STRASBOURG, France and PHILADELPHIA, June 9, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the US Food and Drug Adm ...

• Kurma Partners announces the pricing of Pharvaris IPO

  Paris, Friday 5th February - Kurma Partners a key European player in the financing of innovation in healthcare and biotechnology are proud to announce the successful IPO of one for which Kurma Partners acted as founder investor together with Life Sciences Partners (LSP) in 2016 : Pharvaris. Pharv ...

• UniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

  Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing Technology Large Opportunity Targeting an Estimated 1.3 million TLE Patients in the U.S. ...

• DNA Script Announces the Commercial Launch of the SYNTAX System, the First Benchtop DNA Printer Powered by Enzymatic Synthesis, to Accelerate Molecular Biology and Genomics Workflows

  The SYNTAX System Prints DNA on Demand, Bringing Workflow Control Back to the Lab SOUTH SAN FRANCISCO, Calif., and PARIS, June 15, 2021 - DNA Script, a pioneer in DNA printing on demand, today announced the commercial launch of their SYNTAX platform with their first product, the SYNTAX System ...

• Omnidoc annonce avoir finalisé une levée de fond de 3 millions d’euros pour développer sa solution de téléexpertise

    Ce premier tour de table est mené par Kurma Partners et Newfund, avec la participation de business angels et de la BPI L’enjeu principal de la levée est de développer la solution afin qu’elle s’adapte à l’ensemble des professionnels ...

• Unilabs France accélère sa transformation digitale et révolutionne l'expérience des résultats de biologie médicale en signant un partenariat avec la start-up Kiro

  Paris, le 28 juin 2021 : Unilabs France - la plus importante filiale du Groupe Unilabs, leader européen du diagnostic médical et un acteur majeur de la biologie médicale en France, et Kiro, start-up qui développe une plateforme d'intelligence artificielle au service ...

• Amolyt Pharma Announces Appointment of Two Directors

  Elisabeth Svanberg, M.D., Ph.D. brings extensive experience in the development of therapeutics for under-served endocrine, metabolic and other diseases James Hindman has over 30 years of senior financial experience in the pharmaceutical, biologics and medical device industries Lyon, Fr ...

• Asarina Pharma AB (publ) Q2 Report 2021 released

  Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, a ...

• AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

  AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive ...

• Eurazeo aims to consolidate its position as a major player in health care financing by raising its stake in Kurma Partners, a venture capital firm focused on medical innovation and biotechnology

  Paris, September 23, 2021 - Eurazeo today announced its intention to raise its stake in Kurma Partners, a French venture capital firm specializing in biotechnology and medical innovation, to 70.6%. This transaction coincides with Kurma’s launch of a third investment strategy, Growth Opportunit ...

• PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology

  (Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when exam ...

• Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences

  OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches to clinical development in Alzheimer’s and Parkinson’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 30 September 2021 - Asceneuron SA, a clinical stage company dedicated to target ...

• DeepUll Appoints Richard Ivey to its Board of Directors

  Diagnostics industry veteran with forty years’ experience to support DeepUll in its continued development of its early sepsis identification system BARCELONA, Spain - October 4 2021 - DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the e ...

• Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

  • Dr. Olivier Danos PhD, is currently Chief Scientific Officer of RegenxBio • Frederic Chereau MBA, is currently President and CEO of LogicBio Paris, France, 12th October 2021 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on develop ...

• ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

    Publication underscores ImCheck’s pioneering role in Vγ9Vδ2 T cell-based immunotherapy capable of bridging to the adaptive antitumor immune response through a novel family of immune checkpoint targets Evaluation details ICT01’s progression from bench to bedside ...

• PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics

  Paris, FRANCE - October, 25 2021 – PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), announced today that it has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir - PI ...

• Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

  Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data. Mataró, Barcelona, Spain, November 3, 2021 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the deve ...

• PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

  This funding round allocated in tranches, will strengthen PathoQuest’s position as a leading NGS-based biosafety CRO for the biopharmaceutical industry.   Paris, FRANCE, Tübingen, GERMANY - November 9th, 2021 - PathoQuest, a pioneer in the quality control of biologics using Next-G ...

• Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku

  Nippon Shinyaku secures an exclusive option to acquire all development and commercial rights to advance DYN101 for the treatment of myotubular and centronuclear myopathy in Japan; Dynacure retains rights for rest of world STRASBOURG, France and PHILADELPHIA and KYOTO, Nov. 10, 2021 /PRNewswire/ ...

• Asarina Pharma AB (publ) Q3 Report 2021 released

  Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.” FINANCIAL HIGHLIGHTS Signif ...

• Kurma Partners announces the final closing of its Kurma Diagnostics 2 (KDx2) fund at €83 million

  Paris, 2 December 2021 - Kurma Partners exceeded its initial target and reached over €83 million for the final closing of its Kurma Diagnostics 2 (KDx2) vehicle, a pioneering healthtech investment fund in Europe. KDx2 is backed by prominent investors, including its existing investors, the Europ ...

• Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

    Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021. Emergence Therapeutics ...

• IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

  Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody New York, New York - [December 09, 2021]: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune ...

• Corteria Pharmaceuticals Announces Closing of €12M Seed Financing to Advance Portfolio Assets

    Company established with world-class research from leading industry leaders Experienced team advancing therapies for cardiovascular disease Paris, France, December 09th, 2021 - Corteria Pharmaceuticals, a French biotechnology company specialized in the development of intercepti ...

• Meiogenix Announces $13 Million series A financing round led by Sofinnova Partners

  Co-investors include Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments Paris, France, Dec 14, 2021– Meiogenix, an agriculture biotech company using the process of Chromosome Editing to expand genetic diversity in food and agriculture, announced today the closi ...

• Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement

    A collaboration to develop a new class of small molecule mimetics for the treatment of Parkinson's disease and other indications.   Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company. ...

• ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases

    Series B investment led by Forbion and joined by Pontifax and Kurma Partners Investment will fund clinical studies of ARMGO’s lead molecule ARM210, an oral treatment, in development for cardiac and skeletal muscle diseases Ardsley, New York, USA - 20th December 2021 - ARM ...

• Asarina Pharma receives final approval for landmark phase IIa Tourette study

  (Stockholm, Sweden, 22 December 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlog. The phase IIa Tourette study will take place at the ...

• NaoX Technologies lève 4,3 M€ pour développer un électroencéphalographe de nouvelle génération visant à améliorer le diagnostic et le traitement des maladies neurologiques

  Une technologie brevetée : des capteurs miniaturisés embarqués dans de simples écouteurs Une précision du diagnostic possible grâce au traitement par l’IA des données recueillies en vie réelle Un partenariat de 5 ans avec l’H& ...

• Sunrise secures €6.5 million in funding to deploy its sleep apnea diagnostic solution internationally

  NAMUR, Belgium, Dec. 15, 2021 /PRNewswire/ - Sunrise, a healthtech company founded in 2015 in Belgium, has just closed a €3.25 million fundraising round. Led by Kurma Partners, this round of financing, in which the Vives-IUF fund linked to UCLouvain and Namur Invest also participated, has the o ...

• First patient in for landmark Tourette Syndrome study

  (Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen. The Asarina compound being trialled, Sepranolone, is an endogenous neuroster ...

• Asarina Pharma AB (publ) Year-end Report 2021 released

  Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study i ...

• Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the treatment of Hypoparathyroidism

  Top-line data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 LYON, France, and Cambridge, MA, February 28, 2022 - Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the E ...

• Kurma Partners targets €250 million for its first Growth Opportunities fund

  Paris, March 07, 2022 - Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund, which is targeting €250 million, aims to accelerate the growth of ...

• Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism

  Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 LYON, France, and Cambridge, MA, March 16, 2022 Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announc ...

• Kurma Growth Opportunities fund announces its third investment financing french MedTech company Germitec

  Paris, May 10, 2022 - After completing a first closing in March 2022 at €160 million, the Kurma Growth Opportunities fund managed by Kurma Partners announces a third equity investment in Germitec as part of the raising of 11 M€ communicated today - press release attached. Thanks to this ...

• Kurma Partners recrute un/une Office Manager

  KURMA PARTNERS est une société de gestion agréée par l’AMF, en fort développement, localisée Place de la Madeleine à Paris avec un 2e bureau à Munich, qui investit en capital risque dans le domaine des sciences de la vie et de la sant&eac ...

• Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

  Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe, as well as activities required for US approval pathway   Proceeds will also cover activities for extension of indication to entire X-ALD population   The S ...

• ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

  Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trials Series C adds global investors Earlybird, Andera Partners, Invus and patient organization The Leukemia & Lymphoma Society Therapy Acceleration Prog ...

• Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M to further advance breakthrough auto-immune disease therapeutics

  Paris, France, June 30th 2022 - Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partners. The company ...

• Charles.co lève 7 M€ pour développer sa clinique digitale dédiée à la santé masculine

    Initialement spécialisée dans la santé sexuelle masculine, Charles.co va pouvoir déployer son offre de clinique digitale pour homme sur d'autres sujets de santé chroniques. La clinique digitale entend lever les tabous et les freins et aider les h ...

• Ganymed Robotics raises €21M to complete the development of its next generation surgical robot and prepare for a commercial launch

    Kurma Partners participated in the first close of the Series B of Ganymed and joined its Board of Directors. Funds will accelerate the deployment of the Company’s mission to establish a new standard of care for joint replacement interventions. Paris (France), July 7th. 20 ...

• Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

  Paris, France, September 14, 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces it has entered into collaboration with the Institute of Neurodegenerati ...

• Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)

  Mataró, Barcelona, Spain, September 14, 2022 - Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces that it has filed a Marketing Authorization Application (MAA) for its lead candidate le ...

• Amolyt Pharma annonce les résultats positifs d’innocuité et d’efficacité de la deuxième cohorte de son étude de phase 2a évaluant l’AZP-3601 pour le traitement de l’hypoparathyroïdie

    93 % des patients de la deuxième cohorte ont arrêté la supplémentation orale en calcium et en vitamine D active, tout en maintenant une calcémie moyenne dans les valeurs cibles.   L’excrétion urinaire moyenne de calcium sur 24 heur ...

• Xeltis presented promising FIH data on restorative hemodialysis access graft at PVC congress

  Enrollment in Xeltis’ AXESS multi-center clinical trial now successfully completed Xeltis announced very promising preliminary efficacy and safety results from one of the centers participating in the AXESS first-in-human (FIH) clinical trial of our restorative hemodialysis cardiovascular ...

• Patient recruitment completed in landmark Tourette syndrome study

  (Stockholm, 14 October 2022.) Asarina Pharma has completed the recruitment of patients to its Phase IIa clinical study in Tourette syndrome with a total of 28 patients enrolled and the last patient randomized on October 14. The dropout rate in the study remains unexpectedly low. Topline results are ...

• Coave Therapeutics Strengthens Board of Directors

  • Frederic Chereau named Chairman of the Board • Seasoned entrepreneur, Dr Claudia Mitchell, appointed Non-executive Director Paris, France, October 20th, 2022 - Coave Therapeutics (‘Coave’), a biotech company leading the transition of genetic medicine from (ultra) ...

• Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

  The aXess graft turns into a living blood vessel, promising an unprecedented, immediate and durable solution for hemodialysis patients EINDHOVEN, The Netherlands - November 10, 2022 - Xeltis, a medtech company with the most advanced polymer-based restorative cardiovascular devices, announced to ...

• Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

  The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona (Spain) and Düsseldorf (Germany), November 10, 2022 - Minoryx Therapeutics, a late-stag ...

• IO Biotech Provides Business Update

  Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. &n ...

• Amolyt Pharma Announces $130 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

  Funds will be used to complete phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegaly. Lyon, France, and Cambridge, MA, January 6, 2023 - Amolyt Pharma, a global company specialized in developing therapeutic peptides ...

• The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

  Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions Mataró, Barcelona, Spain, January 19, 2023 - Minoryx Therapeutics (“Minoryx”), a Phase 3 clinical stage biotech c ...

• Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

  Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM) Amolyt has obtained the option to license one or more candidates from XOMA for further clinical development wo ...

• Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

  New investors DaVita Venture Group and Invest-NL join syndicate of international investors in series D2 fundraise Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials EINDHOVEN, The Netherlands - 20 February, 2023, Xeltis, a clinical stage medtech ...

• Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

  ASN90, an O-GlcNAcase inhibitor, is a new chemical entity at clinical stage and a promising candidate for the treatment of PSP, a disorder with a high unmet medical need   PSP is a rare neurological condition that causes severe problems with walking, balance, speech, swallowing and visio ...

• Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology

  Combined company to be named Flamingo Therapeutics, focused on advancing Flamingo’s asset danvatirsen in a Phase II trial PEMDA-HN in Head & Neck cancer and IND-ready program targeting MALAT-1 (FTX-001), in oncology   Merger leverages common synergies of Flamingo and Dynacure, ...

• ImCheck Appoints Thomas Civik as Independent Chairman of the Board

  Marseille, France, March 23, 2023 - ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of Directors. With a distinguished career of 30 years in the biopharmaceutical industry, Mr. Civik has extensive experience in bringing oncology innovations t ...

• Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

  Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment Mataró, Barcelona, Spain, April 25, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on t ...

• Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism following Positive End of Phase 2 Meeting with FDA

  The Calypso trial is expected to be the largest Phase 3 trial to date conducted in hypoparathyroidism with topline data expected by end of 2024   In addition to serum calcium control and elimination of standard of care, the study will also assess normalization of urinary calcium as a key ...

• Oxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation

  Nanopore sequencing combined with PathoQuest expertise offers a new approach for biologics manufacturing with real-time, accurate testing for genetic characterisation, cutting months off traditional methods and providing more complete data. OXFORD, England and Paris,France - May 12, 2023 -  ...

• Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

  US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona, Spain, May 31, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on the deve ...

• Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

  CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE6b Retinitis Pigmentosa Regulatory approval received to e ...

• Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly

  LYON, France, and Cambridge, MA, June 5, 2023 - Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the initiation of a Phase 1 clinical trial of the Company’s peptide growth hormone receptor antagonist (GHRA), ...

• ImCheck est lauréate du nouveau programme French Tech 2030

  ImCheck est l’une des 25 start-up/scale-up en santé parmi les 125 sélectionnées pour cette première édition du programme French Tech 2030.   Cette reconnaissance souligne l’engagement d’ImCheck à contribuer aux ambitions du plan ...

• Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

  Professor Gertsch identifies novel transport mechanism and presents new information on mode of action as part of presentation entitled ‘Identification of an Endocannabinoid Reuptake and Recycling Machinery’ Presentation forms part of 10th Gordon Research Conference on ‘Cannabino ...

• ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

  Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Lead molecule ARM210 repairs ‘leaky’ Ryanodine Receptor (RyR) channels to restore intracellular calcium signaling in cardiac and musculoskeletal dis ...

• IO Biotech, Inc. Announces $75 Million Private Placement Financing

  Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, August 7, 2023 (GLOBE NEWSWIRE) - IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company deve ...

• Corteria Pharmaceuticals Announces a €65M ($71M) Financing to Advance Transformational Medicines in Cardiovascular Diseases

  Paris (France), 07 September 2023 - Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US invest ...

• Axithra, a spin-off of imec and Ghent University, raises 10M Euro

  New drug measurement and monitoring technology for accurate assessment of drug concentrations in blood, paves the way for personalized and faster care Leuven and Ghent (Belgium), 5 September, 2023 – Axithra, a new spin-off of imec and Ghent University, today announced a 10 million euro ...

• Kurma Partners strengthens team and welcomes Amanda Gett-Chaperot as Partner to the Biofund venture team

  Kurma welcomes Amanda Gett-Chaperot as a Partner based in Paris. Amanda brings venture, industry and research experience, well aligned with our Biofund investment strategy. Kurma’s Biofunds constitute our therapeutic venture franchise, investing at pre-seed stage to growth capital, with a s ...

• Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

  Patients from the Canadian National Hypoparathyroidism Registry were prospectively screened for bone disease through DXA scan with results demonstrating significant rates of osteopenia, osteoporosis and associated fragility fractures in postmenopausal females Analysis of translational data from p ...

• Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

  Financing will support the growth of an integrated specialty pharmaceutical company CAMBRIDGE, Mass. - Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ G ...

• Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma ’s portfolio companies

  Samsung Biologics to provide de risking, development , manufacturing services and seamless transitions for biologics from early stages of development to large scale commercialisation   The partnership will streamline gene to IND process to accelerate lead candidate selection and advance ...

• Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

  Commercialization to begin in the United States immediately   US- Ireland Pharmaceutical company expands its oral oncology pipeline October 25, 2023 - CAMBRIDGE, Mass. and London - Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind ...

• Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX

  As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD) Mataró, Barcelona, Spain, November 16, 2023 - Minoryx Therapeutics, a registration stage biotech company focu ...

• Shorla Oncology & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO, the First and Only Oral Methotrexate Solution Approved in the U.S. for Adults

  Cambridge, Mass. & Chicago - December 19, 2023 - Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, and EVERSANA®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of JYLAMVO (methotrexa ...

• Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline

  Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease   Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with participation fr ...

• Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer

  U.S.-Ireland Specialty Pharmaceutical Company’s ready-to-dilute form of a drug for the treatment of adenocarcinoma of the breast or ovary January 9, 2023 - CAMBRIDGE, Mass. - Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the ...

• Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

  Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders   Clinical Trial will investigate the safety, tolerability and phar ...

• Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

  ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinica ...

• ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

  Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg dosing of ARM210 daily in patients with Ryanodine Receptor 1 Related Myopathies   Provides first signs of clinical efficacy improving fatigue and proximal muscle strength in patients at 200 mg daily   ...

• Update on Regulatory Review of leriglitazone in the EU

  A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following the negative CHMP opinion on X-linked adrenoleukodystrophy (X-ALD) Barcelona, Spain and Düsseldorf, Germany - 26 January, 2024 - Minoryx Therapeutics, a late stage biotech company focused on the developme ...

• Kurma Partners Proudly Announces the Acquisition of its Portfolio Company Amolyt Pharma by AstraZeneca

  Following Emergence and Corlieve, Amolyt marks the third major exit of Kurma Biofund III and the first exit of Kurma Growth Opportunities Fund, showcasing the team's unique expertise in transforming European research into biotech leaders. Paris, March 14, 2024 - AstraZeneca announced that i ...

• Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

  Second FDA Acceptance for an NDA Filing by Shorla Oncology Announced in 2024 New Oral Liquid Drug from the U.S. -Ireland Pharmaceutical Company Slows or Stops the Growth of Certain Types of Leukemia and Other Cancers April 08, 2024 7:00 AM Eastern Daylight Time CAMBRIDGE, Mass. -& ...

• Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain

  In a French early-access program study, 10 of 13 patients were clinically and radiologically stable Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics (“Minoryx”), a late-stage biotech company focused on the development of therapies for orphan central nervous syst ...

• Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million

  24 June 2024 - 08:45 GMT+1, DUBLIN and PARIS - (BUSINESS WIRE) - Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-see ...

• Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer

  TEPYLUTE is a ready-to-dilute formulation of thiotepa that significantly reduces preparation time and enables accurate dosing CAMBRIDGE, Mass., June 28, 2024 - Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Dr ...

• SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

  The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 - SciRhom GmbH, a biopharmaceutical company pioneeri ...

• Kurma Partners Proudly Announces the Completion of the Previously Announced Acquisition of its Portfolio Company Amolyt Pharma by AstraZeneca

  Following Emergence and Corlieve, Amolyt marks the third major exit of Kurma Biofund III and the first exit of Kurma Growth Opportunities Fund, showcasing the team's unique expertise in transforming European research into biotech leaders. Paris, July 15, 2024. AstraZeneca today announced the ...

• The US Food and Drug Administration Grants First-Ever De Novo (Ultraviolet radiation disinfection chamber device) for Germitec’s Chronos®, a Chemical-Free UV-C High-Level Disinfection (HLD) Device for Endocavitary and External Ultrasound Probes

  Infection prevention is a significant global public health issue and a top priority for the US healthcare system.   Each year, 1.7 million patients in the US contract Healthcare-Associated Infections (HAIs), leading to 99,000 deaths.   During the rigorous FDA's De Novo proce ...

• Kurma Growth Opportunities and Eurazeo invest in the EUR 93 million financing of PanTera to establish commercial-scale production of actinium-225

  The EUR 93 million oversubscribed fundraise led by EQT Life Sciences alongside Kurma, Eurazeo, Korys, Paladin and PMV aims to pioneer a new commercial-scale production of actinium-225 through the Gamma route in Belgium for one of the most promising radioisotopes in the field of precision oncology ...

• Kurma Partners achieves first close of new EUR 250 million Biofund IV

  Biofund IV raised EUR 140 million in first closing of EUR 250 million fund Biofund IV to follow Kurma’s proven investment strategy and make 16 to 20 new investments First three investments of the new fund already made • Landmark exits, strong financings in Biofund III portfolio pro ...

• SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

  Transition into clinical-stage development marks a significant corporate and R&D milestone Munich, Germany, October 17, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, today announced that the dosing of partici ...

• Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

  Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease   Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025. Barcelona, Spain and Düsseldo ...

• Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines

  Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing investors   Proceeds to advance Coave’s proprietary ALIGATER™ platform to enhance targetin ...

• Germitec Secures $30 Million Financing to Accelerate U.S. Market Expansion and Drive Innovation in UV-C High-Level Disinfection

  Investment firm Eurazeo leads the round, joined by existing shareholders and the management team of the company.   Germitec raises $30 million to fuel U.S. growth and accelerate product innovation.   Funds to drive adoption and commercialization of Germitec’s cutting-edge ...

• Kurma Partners’ portfolio company Stilla Technologies to be Acquired by Bio-Rad Laboratories for $225 Million, Accelerating Growth and Innovation in Digital PCR instruments and tests

  Paris, 17 February 2025 - Kurma Partners announces the acquisition of its portfolio company Stilla Technologies, a leading developer of cutting-edge digital PCR (dPCR) solutions, by Bio-Rad for $225m as well as potential future contingent milestone payments for a maximum amount of up to $50m. The tr ...

• Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial

    Trial continues as planned to 52 weeks to further characterise the risk-benefit profile High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statist ...

• Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer

  AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology   Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications   ...

• Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy

  Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund   Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-relat ...

• Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders

    Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders   First-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs such as keta ...

• EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease

  EvlaBio secures €21 million Seed Funding to complete preclinical development and progress towards IND-enabling studies.   The financing round is led by Kurma Partners as well as AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF.   EvlaBio&rs ...

• Kurma Growth Opportunities Fund co-leads EUR 84 million financing of NUCLIDIUM to scale copper-based radiopharmaceutical platform

    NUCLIDIUM closes EUR 84 million Series B financing to advance the clinical development of its copper-based radiopharmaceutical platform led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech ...

• Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads

         Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (a Citadel company) and aMoon, and with renewed participation from all existing shareholders, including Ponti ...

• Kurma Partners, member of the Eurazeo Group, founding investor of ImCheck Therapeutics, announces the sale of the biotech company to Ipsen for up to €1 billion

    Kurma supported the creation of ImCheck in 2015 based on the scientific research of Professor Daniel Olive.   ImCheck is developing a new generation of immunotherapy antibodies targeting various solid and hematological cancers.   The sale price is €350 million, to ...

• Damae Medical raises €15M in Series B funding to accelerate the transformation of dermatological care through 3D digital biopsies and AI

  Paris, November 26, 2025 - Damae Medical, a French pioneer in imaging and AI for skin cancers, announces a €15M Series B funding round led by Creadev, with participation from Kurma Partners, ISPB, and BNP Paribas Développement. This funding will accelerate the deployment of the deepLi ...

• Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity

    Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors   Matthew Baker appointed as CEO   Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejectio ...

• Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

  Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management with improved quality of weight loss and long-te ...

• PathoQuest, a Kurma Partners portfolio company, announces a definitive agreement to be acquired by Charles River Laboratories

  PathoQuest was built and supported by Kurma Partners and the Pasteur Institute and based on the groundbreaking work of Prof. Marc Eloit Paris, France, January 12, 2026 - PathoQuest, a Kurma Partners portfolio company, pioneer and global leader in Next Generation Sequencing (NGS)-based biosa ...

• Medincell annonce le succès de son Placement Privé d’environ 48 millions d’euros

  Succès de l’opération avec 48 millions d’euros levés.   Participation d’investisseurs internationaux de premier plan spécialisés en santé.   Les fonds levés visent à soutenir la création de vale ...

• Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs

  Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m.   Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and au ...

• Kurma Partners, an Eurazeo Group Compagny, closes €215 Million Biofund IV

  Total Assets Under Management (AUM) across all Kurma Partners franchises now stand at €1 billion.   Kurma bridges gap between European academic research, industry, and investors to deliver disruptive therapeutic solutions, acting as a leading venture builder in the European biotech ...

• NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

  Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany - 24 July, 2026 - Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Comm ...

• Thierry Laugel
• Rémi Droller
• Vanessa Malier
• Philippe Peltier
• Alain Horvais
• Peter Neubeck
• Séverine Pénot
• Sylvain Cascarino
• Muriel Domine
• Théo Esposito
• Hadrien Bouchez
• Amine Marouf
• Laurent Jacqueroud
• Alain Munoz
• Louis Nisbet
• Dr Khalid Islam
• Heiner Dreismann
• Jochen Knolle
• Marion Pouillard
• Benjamin Belot
• Clémence Monteaux
• Cyril Bedran
• Jean-François Rivassou
• Steffi Minga
• Fatima Boubnad
• Daniel Parera
• Laura Achach
• Florence de Coorebyter
• Katrien Swerts
• Maylis Deschamps
• Amanda Gett
• Louise-Marie Rakotoarison
• Samantha Zennou
• Anna Tchorzewska
• Sonny Guilhem
• Ornella Gomis
• Noa Feldman